Prospective Pilot Trial of Dexmedetomidine Sedation for Awake Diagnostic Flexible Bronchoscopy
Rattachement africain : au, nz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Dexmedetomidine has the favorable properties of sedation, sympatholysis, analgesia, and a low risk of apnea. These properties suggest that dexmedetomidine may be useful in procedural sedation. In view of this, we conducted a pilot trial to determine the feasibility of using dexmedetomidine as a sole agent for providing sedation during awake diagnostic flexible bronchoscopy. Patients presenting for awake diagnostic flexible bronchoscopy consented to participate in a trial of dexmedetomidine sedation for the procedure. In addition to local anesthetic topicalization of the airways, dexmedetomidine was infused at 0.5 μg/kg over 10 minutes followed by an infusion of 0.2 to 0.7 μg/kg/h titrating to a Ramsay Sedation Scale score of 3. Hemodynamic parameters (heart rate, blood pressure), oxygenation status (pulse oximetry), adverse events, use of rescue sedation, and patient and proceduralist satisfaction were recorded during the trial. Five of 9 recruited patients required rescue sedation to allow the procedure to proceed. Dexmedetomidine as a sole agent at an infusion of 0.5 μg/kg over 10 minutes followed by an infusion of 0.2 to 0.7 μg/kg/h is unable to provide adequate sedation for awake diagnostic flexible bronchoscopy without the need for rescue sedation in a large proportion of patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prospective Pilot Trial of Dexmedetomidine Sedation for Awake Diagnostic Flexible Bronchoscopy
- Date Crossref
- 01/10/2010
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The Royal Melbourne Hospital Department of Anaesthesia and Pain Management pays non établi dans la noticeOrganisme public
-
Australian and New Zealand Intensive Care Society pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Trials New Zealand pays non établi dans la noticeStructure de recherche
-
Australian New Zealand Clinical Trials Registry: ACTRN12608000304336 pays non établi dans la noticeÉtablissement de santé
-
Conflicts of Interest: None pays non établi dans la noticeInstitution
-
Disclaimer: Hospira Pty Ltd (Australia) provided the trial drug (dexmedetomidine) unconditionally with no input into the study design. None of the authors has received any other sponsorship from Hospira Pty Ltd (Australia) pays non établi dans la noticeEntreprise
-
Funding Sources: Hospira Pty Ltd (Australia) provided the trial drug unconditionally with no input into the study design pays non établi dans la noticeEntreprise
Department of Anaesthesia and Pain Management — The Royal Melbourne Hospital, Australian and New Zealand Intensive Care Society et Clinical Trials New Zealand, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.